Protein / target
Nectin-4
Protein at a glance
Biological role
Cell adhesion mediator activity
Strongest disease association
Ectodermal dysplasia - syndactyly syndrome
Therapeutic maturity
Clinically validated target
Druggability
Antibody
Clinical development
1 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells
Subcellular location
Domains and Gene Ontology detail (13)Hide
Domains & features
Gene Ontology
- Cadherens junction
- Cextracellular exosome
- Cplasma membrane
- Fcell adhesion mediator activity
- Fidentical protein binding
- Freceptor ligand activity
- Fvirus receptor activity
- Pheterophilic cell-cell adhesion
- Phomophilic cell-cell adhesion
- Pnegative regulation of natural killer cell mediated cytotoxicity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell adhesion
- ·Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interac…
- ·Cell junction, adherens junction
- ·cell adhesion mediator activity
- ·heterophilic cell-cell adhesion
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Nectin-4 binding agent
Appears in clinical studies involving urothelial carcinoma, transitional cell carcinoma, neoplasm, urinary bladder carcinoma
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 292 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 1 total
urothelial carcinoma · transitional cell carcinoma · neoplasm
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
- New publication<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
- New publicationEnfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- New publicationThe Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
- New publicationEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
- New publicationEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.